431 related articles for article (PubMed ID: 28862945)
1. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
[TBL] [Abstract][Full Text] [Related]
2. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease.
Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B
Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176
[TBL] [Abstract][Full Text] [Related]
3. Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark.
Safai N; Carstensen B; Vestergaard H; Ridderstråle M
BMJ Open; 2018 Mar; 8(3):e019214. PubMed ID: 29550776
[TBL] [Abstract][Full Text] [Related]
4. Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study.
Nichols GA; Joshua-Gotlib S; Parasuraman S
J Gen Intern Med; 2013 May; 28(5):691-7. PubMed ID: 23345072
[TBL] [Abstract][Full Text] [Related]
5. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
[TBL] [Abstract][Full Text] [Related]
7. Change in cardiovascular risk factors in relation to diabetes status: the Tromso Study.
Joseph J; Svartberg J; Njølstad I; Schirmer H
Eur J Prev Cardiol; 2012 Jun; 19(3):551-7. PubMed ID: 21505026
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous control of diabetes mellitus, hypertension, and hyperlipidemia in 2 health systems.
Schroeder EB; Hanratty R; Beaty BL; Bayliss EA; Havranek EP; Steiner JF
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):645-53. PubMed ID: 22851534
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study.
Leśniak W; Bała MM; Płaczkiewicz-Jankowska E; Topór-Mądry R; Jankowski M; Sieradzki J; Banasiak W;
Cardiol J; 2015; 22(2):150-9. PubMed ID: 25299503
[TBL] [Abstract][Full Text] [Related]
11. Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study.
Al-Shamsi S; Regmi D; Govender RD
BMC Cardiovasc Disord; 2019 Jun; 19(1):148. PubMed ID: 31208354
[TBL] [Abstract][Full Text] [Related]
12. Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study.
Al-Salameh A; Bucher S; Bauduceau B; Benattar-Zibi L; Berrut G; Bertin P; Corruble E; Danchin N; Derumeaux G; Doucet J; Falissard B; Forette F; Hanon O; Ourabah R; Pasquier F; Pinget M; Ringa V; Becquemont L
Can J Diabetes; 2018 Aug; 42(4):365-371.e2. PubMed ID: 29037572
[TBL] [Abstract][Full Text] [Related]
13. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study.
Fung CSC; Wan EYF; Chan AKC; Lam CLK
BMC Cardiovasc Disord; 2017 Jun; 17(1):166. PubMed ID: 28645252
[TBL] [Abstract][Full Text] [Related]
14. Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings.
Minutolo R; Sasso FC; Chiodini P; Cianciaruso B; Carbonara O; Zamboli P; Tirino G; Pota A; Torella R; Conte G; De Nicola L
J Hypertens; 2006 Aug; 24(8):1655-61. PubMed ID: 16877970
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
16. Mortality associated with less intense risk-factor control among adults with diabetes in the United States.
Saydah SH; Gregg EW; Kahn HS; Ali MK
Prim Care Diabetes; 2018 Feb; 12(1):3-12. PubMed ID: 28797537
[TBL] [Abstract][Full Text] [Related]
17. Socioeconomic position and cardiovascular risk factors among people with screen-detected Type 2 DM: six-year follow-up of the ADDITION-Denmark trial.
Dalsgaard EM; Vestergaard M; Skriver MV; Borch-Johnsen K; Lauritzen T; Sandbaek A
Prim Care Diabetes; 2014 Dec; 8(4):322-9. PubMed ID: 24613817
[TBL] [Abstract][Full Text] [Related]
18. HEMOGLOBIN A1C, BLOOD PRESSURE, AND LDL-CHOLESTEROL CONTROL AMONG HISPANIC/LATINO ADULTS WITH DIABETES: RESULTS FROM THE HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL).
Casagrande SS; Aviles-Santa L; Corsino L; Daviglus ML; Gallo LC; Espinoza Giacinto RA; Llabre MM; Reina SA; Savage PJ; Schneiderman N; Talavera GA; Cowie CC
Endocr Pract; 2017 Oct; 23(10):1232-1253. PubMed ID: 28816530
[TBL] [Abstract][Full Text] [Related]
19. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
Zhang J; Shao Y; Liu Y; Tao J
Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
[TBL] [Abstract][Full Text] [Related]
20. Personalised treatment targets in type 2 diabetes patients: The Dutch approach.
Boels AM; Hart HE; Rutten GE; Vos RC
Prim Care Diabetes; 2017 Feb; 11(1):71-77. PubMed ID: 27633894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
